All News

There is much more to a nation's "brain power" than how much it spends on R&D and education. The OECD tries to assess the broader picture by looking at "Investment in knowledge".

The Semiconductor Industry Association in the USA is worried that the country will lose its "leadership in innovation and technology".

Napatech, a Danish company that specialised in raising the speed of Internet network appliances, said it has received $5 million from Ferd Venture, Northzone Ventures and existing shareholder DTU Innovation, a fund which is related to the Danish Technical University.

Deloitte's web site has a special section of detailed analysis of the UK budget and its support for R&D.

The President of the European University Association warns universities to get their act together. Governments come in for some stick too.

The latest budget for the UK continued the Chancellor's role as puppetmaster for science and technology.

Who should benefit from the transfer of technology from the academic world into the business arena? The university that cooked up the ideas, or the company that turned them into money? How about society as a whole? An American Prof warns against micro managing the process.

Microsoft has stepped up its courtship of the international research community with the publication of an investigation of how computer science will underpin scientific discovery in the next 15 years.

If your business isn't in a technology cluster, you have every reason to feel an outsider.

Everyone sees MIT as a role model, especially the British government. But there are other successful exploiters of academic R&D.

Business angels in German-speaking countries have traditionally been shy about what they do. Mary Lisbeth D'Amico watches them come out of hiding.

Chameleon BioSurfaces, a spin-out from the John Innes Centre in Norwich, UK, is looking for £500,000 in funding to develop a new form of polymer coating for drug eluting stents.

Battle lines are drawn in an expensive, distracting and unedifying legal fight between two vaccine manufacturers. Nuala Moran investigates.

Six volunteers are in intensive care after a U.K. trial of an antibody treatment for leukaemia went horribly wrong, raising a raft of questions about drug testing.